Renalys moves to start Phase III in IgA nephropathy after clinching $38M
17 Jul 2024
After launching in January, Japanese drug developer Renalys Pharma has now closed a JPY 6 billion ($38.4 million) series A to start a registrational study of its IgA nephropathy candidate, which it in-licensed earlier this year from Travere Therapeutics.
Renalys has rights to sparsentan in Japan, where it is initially undergoing clinical development, as well as in South Korea, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam, while Travere maintains rights outside of the specified Asia countries.
The dual endothelin angiotensin receptor antagonist boasts accelerated approval in the US and conditional approval in the EU for IgA nephropathy under the name Filspari. Travere filed for a full approval with the FDA in March.
Renalys’ Phase III study of sparsentan is scheduled to start in the second quarter of the Japanese fiscal year, which runs from July to September. Data are expected in the second half of 2025.
Catalys Pacific and SR One, which co-founded Renalys, led Wednesday’s round. Other participating investors include JPS Growth Investment, Sumitomo Mitsui Trust Bank, Japan Co-Invest IV, and NVCC NO.9 Investment.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.